- Previous Close
21.59 - Open
21.59 - Bid 21.85 x 1000
- Ask 21.92 x 3000
- Day's Range
21.28 - 21.98 - 52 Week Range
20.92 - 31.54 - Volume
45,199,720 - Avg. Volume
49,489,493 - Market Cap (intraday)
124.261B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
15.54 - EPS (TTM)
1.41 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield 1.72 (7.49%)
- Ex-Dividend Date Jan 24, 2025
- 1y Target Est
30.54
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
www.pfizer.com81,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PFE
View MorePerformance Overview: PFE
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PFE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PFE
View MoreValuation Measures
Market Cap
124.26B
Enterprise Value
167.43B
Trailing P/E
15.54
Forward P/E
7.45
PEG Ratio (5yr expected)
0.52
Price/Sales (ttm)
1.96
Price/Book (mrq)
1.41
Enterprise Value/Revenue
2.63
Enterprise Value/EBITDA
9.24
Financial Highlights
Profitability and Income Statement
Profit Margin
12.62%
Return on Assets (ttm)
4.64%
Return on Equity (ttm)
9.06%
Revenue (ttm)
63.63B
Net Income Avi to Common (ttm)
8.02B
Diluted EPS (ttm)
1.41
Balance Sheet and Cash Flow
Total Cash (mrq)
20.48B
Total Debt/Equity (mrq)
76.18%
Levered Free Cash Flow (ttm)
12.78B